These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21479688)

  • 1. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD133 mRNA expression and microsatellite instability in colorectal carcinoma.
    Huh JW; Park YS; Lee JH; Kim HR; Shin MG; Kim YJ
    J Surg Oncol; 2010 Dec; 102(7):765-70. PubMed ID: 20872808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
    Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
    BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
    Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
    Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.
    Shin JH; Lee YS; Hong YK; Kang CS
    J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
    Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
    Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
    Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
    Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma.
    Zhang C; Xu Y; Zhao J; Fan L; Jiang G; Li R; Ling Y; Wu M; Wei L
    Ann Surg Oncol; 2011 Aug; 18(8):2373-80. PubMed ID: 21331808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
    Poon MW; Zhuang JT; Wong ST; Sun S; Zhang XQ; Leung GK
    Anticancer Res; 2015 Dec; 35(12):6487-95. PubMed ID: 26637861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
    Wu X; Wu F; Xu D; Zhang T
    J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.